Chair and Master of Ceremonies (Emcee) – Dr. Mathai Mammen, Chairman & CEO, FogPharma

Welcome address: Karun Rishi, President, USAIC

Opening comments: Dr. Mathai Mammen, Chairman & CEO, FogPharma

Panel: Clinical Trials Opportunities in India

Panelists:
Badhri Srinivasan, Head, Global Clinical Operations, Novartis
Dr. Christopher Corsico, Global Head of Development, GSK
Peyton Howell, Chief Operating & Growth Officer, Parexel
Dr. Sarah Sheikh, Head of Global Development, Takeda
Dr. Uli Broedl, SVP, Head of Global Clinical Development, Boehringer Ingelheim
Moderator:
Peter Ronco, Chief Executive Officer, Emmes

Panel: Rare & Neuro Diseases

Panelists:
Dr. David Meeker, Chairman & CEO, Rhythm Pharmaceuticals
Dr. Ed Kaye, President & CEO, Stoke Therapeutics
Dr. James Wilson, Director- Gene Therapy Program, University of Pennsylvania
Josh Mandel-Brehm, President & CEO, CAMP4
Dr. Priya Singhal, Executive Vice President & Head of Development, Biogen
Moderator:
Dr. William Chin, Professor of Medicine, Emeritus, Harvard Medical School

Fireside Chat (Hybrid)
Dr. Robert Califf, Commissioner of Food and Drugs, US Food and Drug Administration
Moderator:
Dr. William Chin, Professor of Medicine, Emeritus, Harvard Medical School

Panel: BioPharma Industry & Investment Outlook

Panelists:
Christopher Viehbacher, President & CEO, Biogen
Dilip Shanghvi, Founder & Managing Director, Sun Pharmaceutical Industries
Hari Bhartia, Founder and Co-Chairman, Jubilant Bhartia Group
Rajiv Kaul, Sector Portfolio Manager, Fidelity Investments
Dr. Stelios Papadopoulos, Chairman of the Board, Exelixis
Moderator:
Daphne Zohar, Founder & Chief Executive Officer, Seaport Therapeutics

Panel: Industry Academic Partnerships

Panelists:
Dr Andrew Plump, President of Research & Development, Takeda
Dr. George Daley, Dean, Harvard Medical School
Dr. Marc Tessier-Lavigne, President Emeritus, Stanford University
Dr. Noubar Afeyan, Founder & Chief Executive Officer, Flagship Pioneering
Moderator:
Dr. Elias Zerhouni, Vice Chairman & President, OPKO Health

Panel: Research & Development Strategies and Trends

Panelists:
Dr Andrew Plump, President of Research & Development, Takeda
Dr. Jane Grogan, Executive Vice President and Head of Research, Biogen
Dr. Mathai Mammen, Chairman & CEO, FogPharma
Dr. Robert Plenge, EVP, Chief Research Officer, Head of Research, Bristol Myers Squibb
Moderator:
Dr. Martin Mackay, Co-Founder, Rallybio

Panel: Oncology

Panelists:
Dr. Bruce Chabner, Director of Clinical Research, Cancer Center, Mass General Hospital
Dr. Claire Mazumdar, Chief Executive Officer, Bicara Therapeutics
Phuong Khanh (P.K.) Morrow, Head of the Oncology Therapeutic Area Unit, Takeda
Dr. Simrit Parmar, Founder, Cellenkos
Dr. Zandy Forbes, President & CEO, MeiraGTx
Moderator:
Dr. Sam Waksal, Founder, Chairman & CEO, Graviton Biosciences

Panel: Digital & Data Science in Healthcare

Panelists:
Dr. Dina Katabi, Professor of Computer Science, MIT
Dr. Jason Kelly, Co-Founder & CEO, Ginkgo Bioworks
Dr. Krishna Yeshwant, Managing Partner, Google Ventures
Michael Nally, Chief Executive Officer, Generate:Biomedicines
Sastry Chilukuri, Chairman & CEO, Emmes Group
Moderator:
Dr. Najat Khan, Chief Data Science Officer, Johnson & Johnson Innovative Medicine

Strategy Sessions Co-Chairs:

Clinical Trials Strategy Session
Dr. Amy McKee, Chief Medical Officer Global Head, Oncology Center of Excellence, Parexel
Badhri Srinivasan, Head, Global Clinical Operations, Novartis
Dr. Cynthia Verst, President, Design and Delivery Innovation, R&D Solutions, IQVIA

Digital & Data Science Strategy Session
Chris Benko, Co-Founder & Chief Executive Office, Koneksa Health
Dr. Simone Fishburn, Editor in Chief, BioCentury
Dr. Anil Sawant, Senior Vice President, Merck & Co.

Honouring Dr. Andrew Plump President of Research & Development, Takeda with the Distinguished Service Award

Comments about Dr. Andrew Plump by his past and present colleagues:
Chris Benko, Co-Founder and Chief Executive Officer, Koneksa Health
Chris Viehbacher, President and Chief Executive Officer, Biogen
Colleen Beauregard, Head, R&D Communications, Learning, Partnerships and Policy, Takeda
Elias Zerhouni, Vice Chairman & President, OPKO Health
Marc Tessier-Lavigne, Chief Executive Officer, Xaira Therapeutics

Chair and Master of Ceremonies (Emcee) – Dr. Andrew Plump, President of Research and Development, Takeda Pharmaceutical

Welcome address: Karun Rishi, President, USAIC

Opening comments: Dr. Andrew Plump, President of Research and Development, Takeda Pharmaceutical

Panel: BioPharma R&D and Global Supply Chain agenda at G20

Panelists:
Amitabh Kant, G20 Sherpa, G20
Dr. Krishna Ella, Chairman & Managing Director, Bharat Biotech
Sanat Chattopadhyay, President- Manufacturing, Merck & Co.
Moderator:
Kiran Mazumdar-Shaw, Executive Chairperson, Biocon

Panel: Clinical Trials Opportunities in India

Panelists:
Badhri Srinivasan, Head, Global Clinical Operations, Novartis
Dr. Cynthia Verst, President, Design & Delivery Innovation for R&D Solutions, IQVIA
Dr. Naresh Trehan, Chairman, Medanta – the Medicity
Dr. Shiv Kumar Sarin, Chancellor, Institute of Liver and Biliary Sciences
Dr. Vinod Paul, Member, National Institution for Transforming India, the NITI Aayog
Moderator:
Dr. Andrew Plump, President of Research and Development, Takeda Pharmaceutical

Panel: BioPharma Industry & Investment Outlook

Panelists:
Daphne Zohar, Founder & Chief Executive Officer, PureTech Health
Christopher Viehbacher, President & CEO, Biogen
Rajiv Kaul, Portfolio Manager, Fidelity Investments
Dr. Stephen Knight, President & Managing Partner, F-Prime Capital
Theresa Tse, Chairwoman of Board Committee, Sino Biopharmaceutical Limited
Moderator:
Dr. Samuel Waksal, Chairman and Chief Executive Officer, Graviton Biosciences

Fireside Chat
Joaquin Duato, Chairman & CEO, Johnson & Johnson
Moderator:
Kenneth Frazier, Chairman, Health Assurance Initiatives, General Catalyst and former Chairman & CEO, Merck & Co.

Fireside Chat
Dr. Robert Califf, Commissioner of Food and Drugs, US Food and Drug Administration
Moderator:
Dr. William Chin, Professor of Medicine, Emeritus, Harvard Medical School

Panel: Industry Academic Partnerships

Panelists:
Dr. Elias Zerhouni, Vice Chairman & President, OPKO Health
Dr. Marcus Schindler, Executive Vice President, Research & Early Development and Chief Scientific Officer, Novo Nordisk
Dr. Mathai Mammen, CEO Designate, FogPharma
Dr. Phillip Sharp, Institute Professor, Koch Institute, MIT
Dr. Priya Singhal, Executive Vice President & Head of Development, Biogen
Moderator:
Dr. Susan Hockfield, President Emerita, MIT

Panel: Oncology

Panelists:
Dr. Alise Reicin, Chief Executive Officer, Tectonic Therapeutic
Dr. Frank Nestle, Global Head of Research and Chief Scientific Officer, Sanofi
Dr. Kathy Seidl, Vice President, Head of the Oncology Drug Discovery Unit, Takeda
Dr. Katy Rezvani, Professor of Medicine, Chief of Section for Cellular Therapy, Director of Translational Research, MD Anderson Cancer Center
Rehan Verjee, Co-Founder & Chief Executive Officer, Stealth start-up
Moderator:
Dr. James Bradner, Physician Scientist, Former President, Novartis Institutes for BioMedical Research

Panel: Digital & Data Science

Panelists:
Dr. Alice Zhang, Co-Founder & CEO, Verge Genomics
Dr. Anne Heatherington, Head of Data Sciences Institute, Takeda Pharmaceuticals
Dr. Dina Katabi, Professor of Computer Science, Member – CSAIL, Massachusetts Institute of Technology
Dr. Junaid Bajwa, Chief Medical Scientist, Microsoft
Sastry Chilukuri former Co-CEO, Medidata
Moderator:
Dr. Najat Khan, Chief Data Science Officer and Global Head of Janssen R&D Strategy and Operations, Janssen R&D, Johnson & Johnson

Fireside Chat
Dr. Albert Bourla, Chairman and Chief Executive Officer, Pfizer
Moderator:
Dr. Stelios Papadopoulos, Chairman, Biogen

Panel: R&D Strategies and Trends

Panelists:
Dr. Andrew Plump, President of Research and Development, Takeda Pharmaceutical
Dr. Daniel Skovronsky, Executive Vice President, Chief Scientific and Medical Officer, Eli Lilly and Company
Dr. David Reese, Executive Vice President, Research and Development, Amgen
Dr. Fiona Marshall, President, Novartis Institutes for BioMedical Research
Moderator:
Dr. Martin Mackay, Co-Founder, Rallybio

Closing Remarks:
Dr. Andrew Plump, President of Research and Development, Takeda Pharmaceutical

Chair and Master of Ceremonies (Emcee) – Dr. Andrew Plump, President of Research and Development, Takeda Pharmaceuticals

Welcome address: Karun Rishi, President, USAIC

Opening comments: Dr. Andrew Plump, President of Research and Development, Takeda Pharmaceuticals

Panel: Moving Closer to Cure for More Cancer Patients

Panelists:
Dr. Christine Ward, Vice President, Head of Oncology and Cell Therapy, Takeda Pharmaceuticals
Dr. Eric Rubin, Senior Vice President, Therapeutic Area Head Oncology, Early Development, Merck Research Labs
Dr. Samarth Kulkarni, Chief Executive Officer, CRISPR Therapeutics
Dr. Sam Waksal, Chairman and Chief Executive Officer, Equilibre Biopharmaceuticals
Dr. Todd Golub, Director and Founding Core Member, Broad Institute of MIT & Harvard
Moderator:
Dr. Alise Reicin, Chief Executive Officer, Tectonic Therapeutic

Fireside Chat
Alex Gorsky, Executive Chairman, Johnson & Johnson
Moderator:
Christopher Viehbacher, Founding Partner, Gurnet Point Capital

Panel: Clinical Trials Landscape in India

Panelists:
Dr. Cynthia Verst, President, Design & Delivery Innovation for Research and Development Solutions, IQVIA
Dr. Kush Parmar, Managing Partner, 5AM Ventures
Dr. Naresh Trehan, Chairman, Medanta
Peter Ronco, Head of Global Development, Janssen Research and Development, Johnson & Johnson
Dr. Vinod Paul, Member, National Institution for Transforming India, the NITI Aayog
Moderator:
Dr. Andrew Plump, President of Research and Development, Takeda Pharmaceuticals

Panel: Digital & Data Science

Panelists:
Daphne Zohar, Founder & Chief Executive Officer, PureTech Health
Dr. Karen Akinsanya, President of Research and Development, Therapeutics, Schrodinger
Dr. Regina Barzilay, Professor of AI and Health, Massachusetts Institute of Technology
Sastry Chilukuri, Co-Chief Executive Officer, Medidata
Dr. Vipin Gopal, Chief Data & Analytics Officer, Eli Lilly
Moderator:
Chris Benko, Co-Founder and Chief Executive Officer, Koneksa Health

Panel: Pandemics – Where does the world go from here

Panelists:
Dr. Larry Tabak, Acting Director, National Institutes of Health (NIH)
Dr. John Mascola, Chief Scientific Officer, ModeX Therapeutics
Dr. Julie Gerberding, Chief Executive Officer, Foundation for the NIH (FNIH)
Kiran Mazumdar-Shaw, Executive Chairperson, Biocon
Moderator:
Dr. Elias Zerhouni, Professor Emeritus, Johns Hopkins University

Panel: Industry & Investment Outlook

Panelists:
Christopher Viehbacher, Founding Partner, Gurnet Point Capital
Hari Bhartia, Founder & Co-Chairman, Jubilant Bhartia Group
Rajiv Kaul, Portfolio Manager, Fidelity Investments
Dr. Stelios Papadopoulos, Chairman of the Board, Biogen
Moderator:
Jennifer Fox, Chief Financial Officer, Nuvation Bio

Panel: Rethinking Rare: Resolutions for reinvention in a genomic age

Panelists:
Dr. Alfred Sandrock, Chief Executive Officer, Voyager Therapeutics
Charlene Son Rigby, Chief Executive Officer, RARE-X
Paula Soteropoulos, Chairman of the Board, Ensoma
Dr. Philip Larsen, Global Head of Research, Bayer Pharma
Max Bronstein, Assistant Director for Health Innovation, White House Office of Science & Technology Policy
Moderator:
Dr. Timothy Yu, Associate Professor in Pediatrics, Harvard Medical School

Panel: Research and Development Strategies & Trends

Panelists:
Dr. Andrew Plump, President of Research and Development, Takeda Pharmaceuticals
Dr. David Reese, Executive Vice President, Research and Development, Amgen
Dr. John Reed, Global Head of Research and Development, Sanofi
Dr. Mathai Mammen, Executive Vice President, Pharmaceuticals, Research and Development, Johnson & Johnson
Moderator: 
Dr. Martin Mackay, Co-Founder, Rallybio

Closing Remarks and Wrap Up

Dr. Andrew Plump, President of Research and Development, Takeda Pharmaceuticals
Advisory Board Members and Speakers

Chair and Master of Ceremonies (Emcee)– Dr. Andrew Plump, President of R&D, Takeda Pharmaceuticals
Summit Theme: “From N of One to N of a Billion”

Welcome address: Karun Rishi, President, USAIC

Opening comments: Dr Andrew Plump, President of R&D, Takeda Pharmaceuticals

Fireside Chat: Dr. Albert Bourla, Chairman & CEO, Pfizer
Moderator: Dr. Stelios Papadopoulos, Chairman of the Board, Biogen

Panel: India Innovation

Panelists:
Amitabh Kant, Chief Executive Officer, National Institution for Transforming India
Dilip Shanghvi, Managing Director, Sun Pharmaceutical Industries Limited
Prof. K. Vijay Raghavan, Principal Scientific Advisor, Government of India
Dr. Naresh Trehan, Chairman, Medanta Hospital
Moderator:
Sanat Chattopadhyay, President- Merck Manufacturing Division, Merck & Co.

Panel: Rare Disease

Panelists:
Dr. David Meeker, Chairman & CEO, Rhythm Pharmaceuticals
Dr. Frank Bennett, Chief Scientific Officer, Ionis Pharmaceuticals
Dr. John Orloff, Head of Research & Development, Alexion
Dr. Katherine High, President – Therapeutics, AskBio
Majid Jafar, Co-Founder, Loulou Foundation
Moderator:
Dr. Alfred Sandrock, Head of Research and Development, Biogen

Fireside Chat:
Robert Bradway, Chairman & CEO, Amgen
Moderator:
Kiran Mazumdar-Shaw, Executive Chairperson, Biocon

Fireside Chat:
Dr. Francis Collins, Director, National Institutes of Health
Dr. Margaret Hamburg, Former Commissioner, U.S. Food and Drug Administration
Moderator:
Dr. Elias Zerhouni, Professor Emeritus, Johns Hopkins University

Panel: Oncology

Panelists:
Dr. Bruce Chabner, Director of Clinical Research, Massachusetts General Hospital Cancer Center
Dr. Carrie Brownstein, Chief Medical Officer, Cellectis
Dr. Philip Larsen, Global Head of Research, Bayer AG
Dr. Sam Waksal, Founder, MeiraGTx
Vivek Ramaswamy, Founder & Executive Chairman, Roivant Sciences
Moderator:
Dr. Alise Reicin, Chief Executive Officer, Tectonic Therapeutic

Industry & Investment Outlook Panel

Panelists:
Christopher Viehbacher, Managing Partner, Gurnet Point Capital
Dr. Peter Orszag, Chief Executive Officer – Financial Advisory,Lazard Freres
Rajiv Kaul, Portfolio Manager, Fidelity Investments
Dr. Stelios Papadopoulos, Chairman, Biogen
Moderator:
Daphne Zohar, Co-Founder and Chief Executive Officer, PureTech Health

Fireside Chat:
Dr. Janet Woodcock, Acting Commissioner, U.S. Food and Drug Administration
Moderator:
Dr. William Chin, Professor of Medicine, Emeritus, Harvard Medical School

Panel: R&D Strategies & Trends

Panelists:
Dr. Andrew Plump, President of Research & Development, Takeda Pharmaceuticals
Dr. David Reese, Executive Vice President, Research and Development, Amgen
Dr. John Reed, Global Head of R&D, Sanofi
Dr. Mathai Mammen, Global Head of Janssen R&D, Johnson & Johnson
Moderator:
Dr. Martin Mackay, Co-Founder, Rallybio

Panel: Digital & Data Science

Panelists:
Craig Kennedy, Senior Vice President, Merck & Co.
Dr. Daphne Koller, Founder & CEO, insitro
Dr. Karen Akinsanya, Chief Biomedical Scientist, Schrödinger
Dr. Najat Khan, Chief Data Science Officer, Janssen Research & Development
Dr. Robert Califf, Head of Clinical Policy & Strategy, Verily & Google Health
Moderator:
Sastry Chilukuri, President, Acorn AI- Medidata

Closing Remarks:
Dr. Andrew Plump, President of Research & Development, Takeda Pharmaceuticals

Chair and Master of Ceremonies: Dr. Andrew Plump, President of Research and Development, Takeda Pharmaceuticals

Welcome address: Karun Rishi, President, USAIC

Panel Discussion- COVID-19: Where are we now? Where are we going?

Panelists:
Dr. Barry Bloom, Professor & former Dean, Harvard School of Public Health
Dr. George Yancopoulos, Co-Founder, President & CSO, Regeneron
Kiran Mazumdar-Shaw, Executive Chairperson, Biocon
Dr. Rajeev Venkayya, President-Global Vaccines, Takeda
Dr. Richard Hatchett, CEO, Coalition for Epidemic Preparedness Innovations (CEPI)
Moderator:
Dr. William Chin, Professor of Medicine, Emeritus, Harvard Medical School

India Regulatory update:
Dr. Mandeep Bhandari, Joint Secretary, Ministry of Health & Family Welfare, India
Dr. V G Somani, Drug Controller General of India, Central Drug Control Organization
Moderator:
Muna Bhanji, Senior Vice President,  Merck & Co.

Fireside Chat:
Kenneth Frazier, Chairman of the Board and Chief Executive Officer, Merck & Co.
Moderator:
Dr. Stelios Papadopoulos, Chairman of the Board, Biogen

Panel: India Innovation Landscape

Panelists:
Amitabh Kant, Chief Executive Officer, National Institution for Transforming India (NITI)
Hari Bhartia, Founder & C o-Chairman, Jubilant Bhartia Group
Dr. K. Vijay Raghavan, Principal Scientific Advisor, Government of India
Dr. Naresh Trehan, Chairman, Medanta – the Medicity
Moderator:
Sanat Chattopadhyay, President, Merck Manufacturing Division; Merck & Co.

Panel: Oncology: A never ending tunnel?

Panelists:
Dr. Alise Reicin, Former President, Global Clinical Development, Celgene
Dr. Laurie Glimcher, President & CEO, Dana-Farber Cancer Institute
Dr. Philip Larsen, Global Head of Research, Bayer AG
Rehan Verjee, President, EMD Serono
Moderator:
Dr. Raju Kucherlapati, Professor of Genetics, Harvard Medical School

Panel: Industry & Investment Outlook

Panelists: Christopher Viehbacher, Managing Partner, Gurnet Point Capital
Daphne Zohar, Founder & CEO, PureTech Health
Dr. Elias Zerhouni, Professor Emeritus, Johns Hopkins University
Dr. Stelios Papadopoulos, Chairman, Biogen
Moderator:
Dr. Andrew Plump, President of Research & Development, Takeda Pharmaceuticals

Panel: Rare Diseases: No longer forgotten; but more to be achieved

Panelists:
Dr. Alfred Sandrock, Executive Vice President, Research & Development, Biogen
Dr. Daniel Curran, Head of the Rare Diseases Therapeutic Area Unit, Takeda
Dr. David Meeker, Chairman & CEO, Rhythm Pharmaceuticals
Dr. John Orloff, Head of Research & Development, Alexion
Matt Wilsey, Co-Founder & Chairman, Grace Science Foundation
Moderator:
Dr. Steve Uden, Co-Founder, Rallybio

Fireside Chat:
Dr. Roy Vagelos, Chairman of the Board, Regeneron Pharmaceuticals
Moderator:
Dr. Mathai Mammen, Global Head of R&D, Janssen Pharmaceutical Companies of J&J

Panel: Digital & Data Science in Healthcare: Pragmatic Insights from the Real-World

Panelists:
Dr. Anne Heatherington, Head of Data Sciences Institute, Takeda Pharmaceuticals
Arpa Garay, President, Global Pharmaceuticals, Commercial Analytics, Merck & Co.
Dr. Maya Said, Chief Executive Officer, Outcomes4Me
Dr. Najat Khan, Chief Operating Officer, Janssen R&D Data Sciences, Johnson & Johnson
Nina Kjellson, General Partner, Canaan
Moderator:
Sastry Chilukuri, President, Acorn AI- Medidata

Panel: R&D Strategies and Trends: Innovation- The Big I

Panelists:
Dr. Andrew Plump, President of Research & Development, Takeda Pharmaceuticals
Dr. David Reese, Executive Vice President, Research and Development, Amgen
Dr. Hal Barron, Chief Scientific Officer and President, R&D, GlaxoSmithKline
Dr. Mathai Mammen, Global Head of R&D, Janssen Pharmaceutical Companies of J&J
Moderator:
Dr. Martin Mackay, Co-Founder, Rallybio

Master of Ceremonies: Dr Andrew Plump, President R&D, Takeda Pharmaceuticals

Welcome address: Karun Rishi, President, USA India Chamber of Commerce

Fireside Chat:
Mark Abdoo, Acting Deputy Commissioner, U.S. Food and Drug Administration
Dr. Eswara Reddy, Drug Controller General of India, Central Drug Control Organization
Moderator:
Sanat Chattopadhyay, President, Merck Manufacturing Division; Merck & Co.

Presentation on CAR (chimeric antigen receptor) T-cell Therapies

Dr. Carl June, Director of Translational Research, Abramson Cancer Center University of Pennsylvania
Moderator:
Dr. Raju Kucherlapati, Professor of Genetics, Harvard Medical School

Panel: Oncology – The Emperor of BioPharma Development

Panelists:
Dr. Arjun Surya, Co-Founder & CSO, Curadev Pharma
Dr. Christopher Arendt, Head- Immunology Unit and Oncology DDU, Takeda
Dr. David Meeker, President & CEO, KSQ Therapeutics
Dr. Marcela Maus, Director of Cellular Immunotherapy, MGH Cancer Center
Dr. Sanjiv Patel, President & Chief Executive Officer, Relay Therapeutics
Moderator:
Dr. Christiana Bardon, Managing Director, MPM Capital

Panel: Future of Clinical Trials and Drug Development

Panelists:
Dr. Alise Reicin, President, Global Clinical Development, Celgene
Dr. Bruce Chabner, Director of Clinical Research, Mass General Hospital Cancer Center
Dr. Mace Rothenberg, Chief Medical Officer, Pfizer
Dr. Michael Rosenblatt, Chief Medical Officer, Flagship Pioneering
Dr. Rob Scott, Chief Medical Officer, Abbvie
Moderator:
Dr. William Chin, Professor of Medicine, Emeritus, Harvard Medical School

Panel: Manufacturing in the Future

Panelists:
Hari Bhartia, Founder and Co-Chairman, Jubilant Bhartia Group
Mark Abdoo, Acting Deputy Commissioner, U.S. Food and Drug Administration
Dr. Paul McKenzie, Executive Vice President, Pharma Operations & Technology, Biogen
Sanat Chattopadhyay, President, Merck Manufacturing Division; Merck & Co.
Vinay Ranade, Chief Executive Officer, Reliance Life Sciences
Moderator:
Professor N. Venkat Venkatraman, Boston University Questrom School of Business

Panel: One in a million – Emerging trends in Rare Diseases

Panelists:
Dr. Daniel Curran, Head of the Rare Diseases Therapeutic Area Unit, Takeda
David Lucchino, Co-Founder and CEO, Frequency Therapeutics
Dr. Dhaval Patel, Executive Vice President  and Chief Scientific Officer, UCB
Dr. James Wilson, Director- Gene Therapy Program, University of Pennsylvania
Dr. Timothy Yu, Assistant Professor in Paediatrics, Harvard Medical School
Moderator:
Dr. Samarth Kulkarni, Chief Executive Officer, CRISPR Therapeutics

Fireside Chat: Value and Access – The ongoing debate
Christopher Viehbacher, Managing Partner, Gurnet Point Capital
Dr. John Maraganore, Chief Executive Officer, Alnylam Pharmaceuticals
Dr. Stelios Papadopoulos, Chairman, Biogen
Moderator:
Dr. Andrew Plump, President R&D, Takeda Pharmaceuticals

India update on Clinical Trial Regulations
Arun Singhal, Additional Secretary, Ministry of Health & Family Welfare, India
Dr. Eswara Reddy, Drug Controller General of India, Central Drug Control Organization
Moderator:
Karun Rishi, President, USA-India Chamber of Commerce

Panel: Research and Development Strategies and Trends

Panelists:
Dr. Andrew Plump, President R&D, Takeda Pharmaceuticals
Dr. James Bradner, President, Novartis Institutes for BioMedical Research
Dr. Mathai Mammen, Global Head of R&D, Janssen Pharmaceutical Companies of J&J
Moderator:
Dr. Martin Mackay, Co-Founder, Rallybio

Strategy Sessions Co-Chairs:

External Research and Development Strategy Session

Manni Kantipudi, Chief Executive Officer, GVK BIO
Dr. Raj Manchanda, Portfolio Leader, Gates Medical Research Institute
Dr. Ulrich Stilz, Vice President, Novo Nordisk
Dr. Kurt Stoeckli, President and Chief Scientific Officer, Glenmark Pharmaceuticals

Technology Platforms Strategy Session
Sastry Chilukuri, Executive Vice President, Medidata
Colin Hill, Chairman & CEO, GNS Healthcare
Dr. Sridaran Natesan, Vice President, Sanofi
Dr. John Reynders, Vice President, Alexion Pharmaceuticals

Master of Ceremonies: Dr Andrew Plump, Chief Medical & Scientific Officer, Member of the Board of Directors, Takeda Pharmaceuticals

Welcome address: Karun Rishi, President, USA-India Chamber of Commerce

Panel: Industry-Academic Research Partnerships

Panelists:
Dr. Chas Bountra, Chief Scientist, University of Oxford
Dr. Jim Glasheen, Executive Vice Chancellor, UMass Medical School
Dr. Jonathan Epstein, Executive Vice Dean & Chief Scientific Officer, Perelman School of Medicine, University of Pennsylvania
Dr. Nirmal Kumar Ganguly, President, Apollo Hospitals Educational & Research Foundation
Dr. Sridaran Natesan, Vice President, Head – Strategic Initiatives & Scientific Relations, R&D, Sanofi
Moderator:
Juan Harrison, Vice President, Head of Strategic Academic Alliances, Takeda Pharmaceuticals

Panel Discussion: Neuro Diseases

Panelists:
Dr. Alfred Sandrock, Executive Vice President & Chief Medical Officer, Biogen
Dr. David Goldstein, Director, Institute for Genomic Medicine, Columbia University Medical Center
Dr. Maurizio Fava, Associate Dean, Clinical & Translational Research, Harvard Medical
Dr. Meeta Chatterjee, Head, Business Strategy & Ops, BD&L, Merck Research Labs
Dr. Steven Paul, President and CEO, Voyager Therapeutics
Moderator:
Dr. Steve Uden, Co-Founder, Rallybio

Panel: Oncology

Panelists:
Dr. Bruce Chabner, Director of Clinical Research, Mass General Hospital Cancer Center
Dr. Kurt Stoeckli, President and Chief Scientific Officer, Glenmark Pharmaceuticals
Dr. Philip Rowlands, Head of the Oncology TAU, Takeda Pharmaceuticals
Dr. Victoria Richon, President & CEO, Ribon Therapeutics
Dr. Rakesh Jain, Director,  E.L. Steele Laboratory of Tumor Biology, MGH Cancer Center/Harvard Medical School
Moderator:
Dr. Raju Kucherlapati, Professor of Genetics, Harvard Medical School

Fireside Chat
Dr. Ansbert Gadicke, Founder & Managing Director, MPM Capital
Dr. Stelios Papadopoulos, Chairman, Biogen
Dr. Tsutomu Une, Senior Corporate Advisor, GCA Corporation
Moderator:
Dr. William Chin, Professor of Medicine, Emeritus, Harvard Medical School

Panel: Technology Platforms

Panelists:
Chris Benko, Co-Founder and Chief Executive Officer, Koneksa Health
Colin Hill, Chairman & CEO, GNS Healthcare
Dr. Peter Mueller, President, The Mueller Health Foundation
Dr. Shahram Ebadollahi, Vice President, Innovations & CSO, IBM Watson Health Group
Dr. Vijay Chandru, Chairman, Strand Life Sciences
Moderator:
Dr. Ajay Dhankhar, Senior Partner, McKinsey and Company

Presentation- BioPharma: An Extraordinary Disruption

Dr. Ajay Dhankhar, Senior Partner, McKinsey and Company
Sastry Chilukuri, Partner, McKinsey and Company

Panel: Drug Discovery and Development

Panelists:
Dr Andrew Plump, Chief Medical and Scientific Officer, Takeda Pharmaceuticals
Dr. Mathai Mammen, Global Head of R&D, Janssen Pharmaceutical- J&J
Dr. Michael Ehlers, Executive Vice President and Head of R&D, Biogen
Moderator:
Dr. Martin Mackay, Co-Founder and CEO, Rallybio

Fireside Chat
Dr. George Daley, Dean, Harvard Medical School; Dr. Susan Hockfield, President Emerita & Professor of Neuroscience, Massachusetts Institute of Technology (MIT)
Moderator:
Dr Andrew Plump, Chief Medical and Scientific Officer, Takeda Pharmaceuticals

Strategy Sessions Co-Chairs:

External R&D Strategy Session- New Frontiers in External Innovation

Benjamin (Ben) Thorner, Head of Business Development & Licensing, Merck Research Labs
Dr. Ajay Nirula, Vice President- Immunology, Lilly Research Laboratories
Philippe Lopes-Fernandes, Senior Vice President, Merck KGaA, Darmstadt, Germany
Dr. Chandra Ramanathan, Vice President & Head of East Coast Innovation Center, Bayer

Technology Platforms Strategy Session

Dr. Vijay Chandru, Chairman, Strand Lifesciences
Iya Khalil, Co-Founder and Executive Vice President, GNS Healthcare
Dr. Femida Gwadry-Sridhar, Founder and Chief Executive Officer, Pulse Infoframe

Content to be added….

Master of Ceremonies: Dr Andrew Plump, Chief Medical & Scientific Officer, Member of the Board of Directors, Takeda Pharmaceuticals

Welcome address: Karun Rishi, President, USA-India Chamber of Commerce

India Regulatory and Clinical Research Update
Dr. R K Vats , IAS, Additional Secretary, Ministry of Health and Family Welfare, Govt. of India

Panel: Oncology

Panelists:
Dr. Edward Benz, President & CEO Emeritus, Dana Farber Cancer Institute
Dr. Vijay Chandru, Chairman, Strand Life Sciences
Dr. Timothy Clackson, President R&D and CSO, Ariad
Dr. Jeffrey Engelman, Global Head of Oncology Research, NIBR (Novartis)
Dr. Rakesh Jain, E.L. Steele Laboratory of Tumor Biology,  MGH Cancer Center

Moderator:
Dr. Vijay Kuchroo, Director- Evergrande Center, Brigham & Women’s Hospital/Harvard Medical School

Fireside Chat
Dr. Richard Moscicki, Deputy Director (Science Operations), Center for Drug Evaluation and Research, USFDA
Dr. GN Singh, Drug Controller General of India, CDSO, Ministry of Health
Dr. Chris Austin, Director, National Center for Advancing Translational Sciences, National Institutes of Health
Moderator:
Dr. William Chin, Executive Vice President and Chief Medical Officer, PhRMA

Panel: Vaccines

Panelists:
Dr. Stephen Caddick, Director of Innovation, Wellcome Trust
Dr. Johan Van Hoof, Global Therapeutic Head- Infectious Diseases & Vaccines, Janssen Pharmaceutical Companies of Johnson &Johnson
Dr. Gagandeep Kang, Executive Director, Translational Health Science & Technology Institute
Michael Nally, President, Merck Vaccines, Merck & Co
Dr. Niranjan Sardesai, Chief Operating Officer, Inovio Pharmaceuticals
Moderator:
Dr. William Chin, Executive Vice President and Chief Medical Officer, PhRMA

Fireside Chat
Sanat Chattopadhyay, President, Merck Manufacturing Division; Merck & Co.
Dr. R. K. Vats, IAS, Additional Secretary, Ministry of Health and Family Welfare, Government of India

Moderator:
Dr. Amrit Ray, Chief Medical Officer, Janssen Pharmaceutical Companies of Johnson & Johnson

Panel : Clinical Trials & Regulatory

Panelists:
Dr. Richard Moscicki, Deputy Director (Science Operations), CDER, USFDA
Dr. Petra Kaufmann, Director, Office of Rare Diseases Research & Director, Division of Clinical Innovation- NCATS, National Institutes of Health
Dr. GN Singh, Drug Controller General of India, CDSO, Ministry of Health
K.V. Subramaniam, President, Reliance Life Sciences
Dr. Tsutomu Une, Corporate Advisor, GCA Corporation
Moderator:
Dr. Michael Rosenblatt, Chief Medical Officer, Flagship Pioneering

Panel: Rare and Neglected Diseases     

Panelists:
Dr. Chris Austin, Director, National Center for Advancing Translational Sciences, National Institute of Health
Dr. Jim Burns, President and CEO, Casebia Therapeutics
Dr David Meeker, Head, Sanofi Genzyme
Dr. Wim Parys, Head of R&D- Global Public Health, Janssen Pharmaceutical- Johnson &Johnson
Dr. Alfred Sandrock, Executive Vice President & Chief Medical Officer, Biogen
Moderator:
Dr. Steve Uden, Head of Research, Alexion Pharmaceuticals

Panel: Drug Discovery and Development

Panelists:
Dr. James Bradner, President, Novartis Institutes for BioMedical Research
Dr. William Hait, Global Head- Research & Development, Janssen Pharmaceutical- Johnson &Johnson
Dr. David Nicholson, Chief R&D Officer, Allergan
Dr Andrew Plump, Chief Medical & Scientific Officer and Director, Takeda
Moderator:
Dr. Martin Mackay, Exe. Vice President and Global Head of R&D, Alexion Pharmaceuticals

Strategy Sessions Co-Chairs:

Rare & Neglected Diseases strategy session
Petra Kaufmann, MD, Director- Office of Rare Diseases Research, Director- Division of Clinical Innovation, National Institutes of Health (NIH)
Philippe Lopes-Fernandes, Senior Vice-President, Head of Global Business Development & Alliance Management, Merck KGaA
Sanjeev Sinha, MD, Professor, Department of Medicine, All India Institute of Medical Sciences (AIIMS)
Vijay Chandru, PhD, Chairman & CEO, Strand Life Sciences

External R&D strategy session
Manni Kantipudi, Chief Executive Officer, GVK BIO
Robert Urban, PhD, Global Head, Johnson & Johnson Innovation
Sridaran Natesan, PhD, Vice President- Strategic Initiatives & Scientific Relations, Sanofi

Master of Ceremonies: Dr Andrew Plump, Chief Medical & Scientific Officer, Member of the Board of Directors, Takeda Pharmaceuticals

Welcome address: Karun Rishi, President, USA India Chamber of Commerce

India Regulatory and Clinical Research Update
K.L. Sharma, IAS, Joint Secretary, Ministry of Health and Family Welfare, Government of India

Panel: Neurodegenerative diseases- Matters of the mind

Panelists:
Dr. John Dunlop, Vice President & Head, Neuroscience, AstraZeneca
Dr. Douglas Feltner; Philippe Lopes-Fernandes, Senior Vice-President, Merck KGaA
Dr. Alfred Sandrock, Executive Vice President and Chief Medical Officer, Biogen
Dr. Rudolph Tanzi, Director, Genetics and Aging Research Unit, Mass General Hospital
Moderator:
Dr. Ole Isacson, Professor of Neurology, Harvard Medical School

Fireside Chat
Dr David Meeker, Head, Sanofi Genzyme
Dilip Shanghvi, Managing Director, Sun Pharmaceutical Industries Limited
Moderator:
Dr. Raju Kucherlapati, Professor of Genetics, Harvard Medical School

Panel: Drug Discovery and Collaborative Research: The path forward

Panelists:
Dr. Ariz Ahammed IAS, Joint Secretary, Department of Pharmaceuticals, Govt. of India
Dr. Barry Bloom, Distinguished Service Professor, Harvard School of Public Health
Dr. Peter Mueller, President of R&D and Chief Scientific Officer, Pronutria BioSciences
Dr. Andrew Plump, Chief Medical & Scientific Officer, Takeda Pharmaceuticals
Anil Raghavan, Chief Executive Officer, Sun Pharma Advanced Research Company
Moderator
Dr. Steve Uden, Head of Research, Alexion Pharmaceuticals

Fireside Chat
Dr Griffin Rodgers, Director, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health
Moderator:
Dr. William Chin, Executive Vice President, PhRMA

Panel: Oncology- Immuno-oncology, data analytics and value platforms – the new world order

Panelists:
Dr. Bruce Chabner, Director of Clinical Research, MGH Cancer Center
Dr. Arun Chandavarkar, CEO & Joint Managing Director, Biocon
Dr. Gordon Freeman, Professor of Medicine, Dana-Farber Cancer Institute/HMC
Dr. Sandeep Gupta, President & CEO, Asana BioSciences
Dr. Rakesh Jain, E.L. Steele Laboratory of Tumor Biology,  MGH Cancer Center
Dr. Daniel Omstead, President & CEO,Tekla Capital Management
Moderator:
Colin Hill, Chairman & CEO, GNS Healthcare

Panel: Cardiovascular and Metabolic Diseases – Matters of the heart and the body

Panelists:
Neil McDonnell, PharmD, Chief Executive Officer, Metacrine
Dr. Anthony Muslin, Vice President, Head of the Cardiovascular & Fibrosis Unit, Sanofi
Dr. Robert Plenge, VP and  Head of Translational Medicine, Merck Research Labs
Dr. Arthur Tzianabos, President & CEO, Homology Medicines
Dr. Murali Vemula, Founder & President, Nivarta
Moderator:
Dr. Michael Rosenblatt, Executive Vice President & Chief Medical Officer, Merck & Co.

Panel: Regulatory Policies to foster R&D Innovation

Panelists:
Dr. Ariz Ahammed IAS, Joint Secretary, Department of Pharmaceuticals, Govt. of India
Dr. Christopher Corsico, Chief Medical Officer, Boehringer Ingelheim GmbH
Rajiv Kaul, Portfolio Manager, Fidelity Investments
K.L. Sharma, IAS, Joint Secretary, Ministry of Health & Family Welfare, Govt. of  India
Dr. Tsutomu Une, Corporate Advisor, Daiichi Sankyo Co., Ltd.
Moderator:
Dr. William Chin, Executive Vice President, PhRMA

Comments from past Participants (Those who have been participating for 9 years or longer)

Sanjeev Gupta, MD, Professor of Medicine,  Albert Einstein College of Medicine
Amar Sawhney, Chairman & CEO, Ocular Therapeutix
Dinesh Patel, MD, Chief of Arthroscopic Surgery, Mass General Hospital
Vijay Chandru, PhD, Chairman, Strand Life Sciences
Ajay Dhankhar, PhD, Senior Partner, McKinsey & Company
Sunil Shah, Chief Executive Officer, O2h
Manni Kantipudi, Chief Executive Officer, GVK Biosciences
Sridaran Natesan, PhD, Vice President -Strategic Initiatives & Scientific Relations, Sanofi
Christopher Wright, MD, PhD, Chief Medical Officer, Axcella Health
Srini Srinivasan, Managing Director, Hospira Healthcare India
Glenn Kazo, President, Prolong Pharmaceuticals; William Chin, MD, Executive Vice President, PhRMA
Raju Kucherlapati, PhD, Professor of Genetics, Harvard Medical School

Strategy Sessions Co-Chairs:

Genetics & Genomics
Dr. Kush Parmar, Managing Partner, 5AM Ventures
Dr. John Reynders, Vice President, Alexion
Dr. Vijay Chandru, Chairman, Strand Lifesciences

External Research Strategies
Dr. Sridaran Natesan, Vice President, Sanofi USA
Dr. Meeta Chatterjee, Head of Business Strategy and Operations, Merck Research Labs
Dr. Sanjeev Sinha, Professor, All India Institute of Medical Sciences

Content to be added…..

Master of Ceremonies: Dr. Raju Kucherlapati, Professor of Genetics, Harvard Medical School

Welcome address: Karun Rishi, President, USA India Chamber of Commerce

Fireside Chat
Christopher Viehbacher, Puretech Ventures
Dr. Tachi Yamada, Chief Medical & Scientific Officer, Takeda
Moderator:
Dr. William Chin, Executive Vice President, PhRMA

Chief Medical Officer’s Panel: Can the CMO make or break the India value proposition?

Panelists:
Dr. Timothy Garnett, Chief Medical Officer, Lilly Research Laboratories
Dr. Jagdish Prasad, Director General Health Services, Ministry of Health, India
Dr. Amrit Ray, Chief Medical Officer, Janssen
Dr. Maria Rivas, Vice President, Global Medical Affairs, AbbVie
Dr. Michael Rosenblatt, Executive Vice President & Chief Medical Officer, Merck & Co.
Moderator:
Dr. William Chin, Executive Vice President, PhRMA

Panel: Oncology- High potential but high cost – Can emerging markets like India help drive affordable innovation at scale?

Panelists:
Dr. Edward Benz, President & CEO, Dana Farber Cancer Institute
Dr. Bruce Chabner, Director of Clinical Research, MGH Cancer Center
Dr. Vijay Chandru, Chairman & CEO, Strand Life Sciences
Dr. Sandeep Gupta, President & CEO, Asana BioSciences
Dr. Kiran Mazumdar-Shaw, Chairperson & Managing Director, Biocon
Moderator:
Dr. Maya Said, Vice President-Strategy, External Innovation & Science Policy, Sanofi

Panel: Cardiovascular and Metabolic Diseases – How can we turn the tide on the world’s largest culprit for disease burden and mortality?

Panelists:
Dr. Judith Fradkin, Director, Division of DE&MD, NIDDK, National Institutes of Health
Dr. Philip Larsen, Global Head of Diabetes R&D, Sanofi
Dr. Jagdish Prasad, Director General Health Services, Ministry of Health, India
Dr. Peter Stein, VP, Late Stage Development, Diabetes & Endocrinology, Merck Research Labs
Dr. Carani Sanjeevi, Professor, Department of Medicine, Karolinska Institute
Moderator:
Dr. Roger Newton, Founder, Executive Chairman & CSO, Esperion Therapeutics

Panel: Drug Discovery and Collaborative Research- Increasing the odds of success

Panelists:
Dr. Peter Mueller, President of R&D and Chief Scientific Officer, Pronutria BioSciences
Dr. John Orloff, Global Head of R&D, Baxalta
Dr. Andrew Plump, Chief Medical & Scientific Officer Delegate, Takeda
Dr. Kiran Mazumdar-Shaw, Chairperson & Managing Director, Biocon
Dr. Tsutomu Une, Corporate Advisor, Daiichi Sankyo Co., Ltd.
Moderator:
Dr. Martin Mackay, Executive Vice President and Global Head of R&D, Alexion Pharmaceuticals

Panel: Neurodegenerative Diseases – Will we be able to contain the “epidemic” ahead of us?

Panelists:
Dr. Jang-Ho Cha, Global Head, Translational Medicine, Neuroscience, Novartis Institutes for Biomedical Research
Dr. Peter Lansbury, Chief Scientific Officer, Lysosomal Therapeutics
Dr. Darryle Schoepp, VP & Neuroscience TA Head, Early Dev, Merck & Co
Dr. Todd Sherer, Chief Executive Officer, The Michael J. Fox Foundation (MJFF)
K.V. Subramaniam, President, Reliance Life Sciences
Moderator:
Dr. Ole Isacson, Professor of Neurology, Harvard Medical School

Strategy Sessions Co-Chairs

Big Data
Collin Hill, Chairman & CEO, GNS Healthcare
Dr. Azmi Nabulsi, Head of R&D Strategic and Professional Affairs, Takeda
External R&D Strategies
Philippe Lopes-Fernandes, Senior Vice-President, Merck Serono / EMD Serono
Dr. Sandeep Gupta, President & CEO, Asana BioSciences

Release of Position Paper by Advisory Board members
Presentation of USA-India Chamber of Commerce commissioned Position Paper by
Patrick Figgis,  Global Leader, Health and Sujay Shetty, Partner, India Pharma Life Sciences, Pricewaterhouse Coopers LLP

We regret over 100 senior colleagues could not be accommodated in this meeting due to the nature and format of this Strategy Session. Detailed report with recommendations has been sent to the participants, members and key policy makers.

Co-Chairs:

Prof. Ranjit Roy Chaudhury, Chairman- Task Force for Research, Apollo Hospitals
Krishna Ella, Chairman, Bharat Biotech
Dr. G.N. Singh, Drug Controller General of India, Central Drug Control Organization
Dr. Une Tsutomu, Corporate Advisor, Daiichi Sankyo
Dr. M.K. Bhan, Former Secretary to Government of India, Department of Biotechnology
V.K. Subburaj, Secretary to the Government of India, Department of Pharmaceuticals
Davinder Brar, Chairman, GVK Biosciences
Dr, Naresh Trehan, Chairman, Medanta
Dr. Nirmal K. Ganguly, Professor, National Institute of Immunology
Dr. William Chin, Executive Vice President, PhRMA
K.V. Subramaniam, Chief Executive Officer, Reliance Life Sciences
Karun Rishi, President, USA India Chamber of Commerce
Patrick Figgis, Partner & Global Leader –Health, PricewaterhouseCoopers

Delhi Strategy Session reflected on the action agenda emerging from the global summit held in June 2014 in Boston, explored the implications for the decision makers in India and discussed ideas for the June 11, 2015 Boston Summit. PricewaterhouseCoopers facilitated the session. We will take the lead to develop deeper perspectives on these issues through detailed stakeholder discussions, interviews and analyses for discussion at the Boston summit in June 2015

Discussions were held on:
1. India’s potential R&D strengths and steps required to play a leading role in BioPharma & Healthcare innovation
2. Regulatory environment to spur innovation
3. Clinical Trials
4. Suggestions for the 2015 Boston BioPharma Summit

Master of Ceremonies: Dr. Raju Kucherlapati, Professor of Genetics, Harvard Medical School

Welcome Address: Karun Rishi, President, USA-India Chamber of Commerce

Address by: Professor K. VijayRaghavan, Secretary, Department of Biotechnology, Ministry of Science & Technology, Government of India

Address by: Dr. Robert Langer, David H. Koch Institute Professor, MIT

Panel: Biologics and Biosimilars- How will the future landscape shape out and what are the key challenges to overcome?

Panelists:
John Cox, Executive Vice President- Pharma Operations, Biogen Idec
Dr. Richard Gregory, Head of R&D, Sanofi-Genzyme R&D Center
Dr. Mark Schenerman, Vice President- Analytical Biotechnology & Strategy, MedImmune
Rick Srigley, President & CEO, Aragen Bioscience
K.V. Subramaniam, President & CEO, Reliance Life Sciences
Moderator:
Thomas Saylor, Chief Executive Officer, Arecor Limited

Panel:  Industry-Academia Partnerships- Is there a recipe for successful partnerships?

Panelists:
Dr. Karen Antman, Dean and Provost, Boston University School of Medicine
Dr. Sumantra Chattarji, NCBS, Director- Center for Brain Development & Repair, India
Dr. Laurie Glimcher, Dean, Weill Cornell Medical College
Dr. Michael Rosenblatt, Executive Vice President & Chief Medical Officer, Merck & Co.
Dr. Lansing Taylor, Director, University of Pittsburgh Drug Discovery Institute
Moderator:
Dr. William Chin, Executive Vice President- Scientific and Regulatory Affairs, PhRMA

Panel: Reimagining India- Unlocking the potential of Asia’s next superpower

Panelists:
Dr. Yasheng Huang, Associate Dean and Professor, Sloan School of Management- MIT
Ambassador Dnyaneshwar Mulay, Consul General of India, New York
Prof. K. VijayRaghavan, Secretary, Department of Biotechnology, Govt. of India
Dr. Srinath Reddy, President, Public Health Foundation of India
Moderator:
Adil Zainulbhai, Director Emeritus – India Office, McKinsey & Company

Panel: Drug Discovery and Collaborative Research- How can emerging markets play a greater role in BioPharma innovation?

Panelists:
Dr. Subir Basak, President- Global Drug Discovery Services, Jubilant Life Sciences
Dr. Bahija Jallal, Executive Vice President, MedImmune
Manni Kantipudi, Chief Executive Officer, GVK Biosciences
Dr. Andrew Plump, Deputy President of Global R&D, Sanofi
Dr. Tsutomu Une, Corporate Advisor, Daiichi Sankyo Co., Ltd.
Moderator:
Dr. Martin Mackay, Executive Vice President and Global Head of R&D, Alexion Pharmaceuticals

Panel: Cardiovascular and Metabolic Diseases- Science and research trends- Lessening the disease burden through BioPharma innovation

Panelists:
Dr. Caroline Apovian, Professor of Medicine, Section of Endocrinology, Boston University Medical Center
Dr. Daniel Bloomfield, Vice President Clinical Research and  Cardiovascular Therapeutic Area Head, Merck Research Labs
John Brooks, President & CEO, Joslin Diabetes Center
Dr. Philip Larsen, Global Head of Diabetes R&D, Sanofi
Dr. Ming Wang, Vice President and Disease Area Leader of Diabetes, Janssen Pharmaceuticals
Moderator:
Sri Mosur, President, Stabilis and Founder, Tanroe

Release of Position Paper by Advisory Board members
Presentation of USA-India Chamber of Commerce commissioned Position Paper by Dr. Ajay Dhankhar, Director and Dr. Jeffrey Smith, Partner – McKinsey & Company

Cocktails and Networking Reception

We regret over 90 senior colleagues could not be accommodated in this meeting due to the nature and format of this Strategy Session. Detailed report with recommendations has been sent to the participants, members and key policy makers.

Co-Chairs:
Prof. K. VijayRaghavan, Secretary, Department of Biotechnology
Dr. Tsutomu Une, Member of the Board, Daiichi Sankyo
Dr. Naresh Trehan, Chairman, Medanta- The Medicity
Dr. G.N. Singh, Drug Controller General of India
Dr. Willard Dere, Senior Vice President & Global CMO, Amgen
D.S. Brar, Chairman, GVK Biosciences
Prof. N.K. Ganguly, former Director General, Indian Council for Medical Research
K.V. Subramaniam, Chief Executive Officer, Reliance Life Sciences
Dr. Narinder Mehra, Dean for Research, All India Institute of Medical Sciences
Dr. Ajay Dhankhar, Director, McKinsey & Company
Karun Rishi, President, USA-India Chamber of Commerce

Delhi Strategy Session reflected on the action agenda emerging from the global summit held in June 2013 in Boston, explored the implications for the decision makers in India and discussed ideas for the June 27, 2014 Boston Summit. McKinsey & Company facilitated the session. We will take the lead to develop deeper perspectives on these issues through detailed stakeholder discussions, interviews and analyses for discussion at the Boston summit in June 2014.

Discussions were held on:

1. R&D challenges and models: Clinical trials; public-private partnerships
2. Regulatory environment to spur innovation: How can India play a more leading role?
3. Biologics & Biosimilars: Can Indian talent and extensive unmet patient needs be used to help drive further growth and development?
4. Diabetes and Cardiovascular disease: What are disease specific implications on the above topics?

Master of Ceremonies: Dr. Martin Mackay, Exe. Vice President and Global Head of R&D, Alexion Pharmaceuticals

Welcome Address: Karun Rishi, President, USA-India Chamber of Commerce

Address by: Dr. Elias Zerhouni, President- Global Research & Development, Sanofi

Address by: Ravinder Jain, IAS, Additional Secretary, Ministry of Health, Govt. of India

Panel: Oncology: Science and Research Trends – High potential but high cost – Can emerging markets help drive affordable innovation at scale?

Panelists:
Dr. Ramesh Deka, Director, All India Institute of Medical Sciences
Dr. Willard Dere, Senior Vice President & International Chief Medical Officer, Amgen
Dr. Ansbert Gadicke, Managing Partner, MPM Capital
Dr. Richard Gaynor, Vice President- Oncology Development, Eli Lilly and Company
Dr. Rakesh Jain, E.L. Steele Laboratory of Tumor Biology, MGH Cancer Center
Moderator:
Dr. Raju Kucherlapati, Paul C. Cabot Professor, Dept. of Genetics, Harvard Medical School

Panel: Infectious Diseases: Science and Research trends– Can global partnerships address a potentially significant public health challenge?

Panelists:
Dr. Jeffrey Chodakewitz, SVP & Franchise Head – Infectious Diseases, Merck & Co.
Dr. Brian Dannemann, Senior Director, J&J Pharmaceutical R&D
Dr. Lynn Marks, SVP- Projects, Clinical Platforms & Sciences, GlaxoSmithKline
Dr. Mark Namchuk, Senior Vice President- Research, Vertex Pharmaceuticals
Dr. G.N. Singh, Drug Controller General of India, Central Drug Control Organization
Moderator:
Dr. Manos Perros, Head of Infection iMed & Site Head, Boston R&D, AstraZeneca

Panel: Industry-Academic Partnerships/Translational Research: Is there a recipe for successful partnerships?

Panelists:
Dr. Karen Antman, Dean and Provost, Boston University School of Medicine
Dr. Sanjeevi Carani, Associate Professor, Karolinska Institutet
Dr. JC Gutiérrez-Ramos, Group Senior Vice President, Biotherapeutics R&D, Pfizer
Dr. Ashok Kumar, Vice Chancellor, AKS University
Dr. Sridaran Natesan, Vice President, External Innovation (R&D), Sanofi
Moderator:
Dr. William Chin, Executive Dean for Research, Harvard Medical School

Panel: Funding innovation – Building collaborative platforms and supportive policies to foster innovation

Panelists:
Shambhu Kallolikar, IAS, Joint Secretary, Department of Pharmaceuticals, Govt. of India
Peter Michelsen, Managing Director, Goldman Sachs
Dr. Helmut Schühsler, Managing Partner, TVM Capital
Dr. G.N. Singh, Drug Controller General of India, Central Drug Control Organization
K.V. Subramaniam, President & CEO, Reliance Life Sciences
Moderator:
Navjot Singh, Director, McKinsey and Company

Panel: Drug discovery and Collaborative Research- Are existing R&D models doing enough to address the global productivity challenge?

Panelists:
Dr. Subir Basak, President- Global Drug Discovery Services, Jubilant Life Sciences
Dr. Martin Fitchet, Chief Operating Officer, Janssen Research & Development
Dr. Bahija Jallal, Executive Vice President, MedImmune
Dr. Peter Mueller, Exe. Vice President – Global R&D & CSO, Vertex Pharmaceuticals
Dr. Maya Said, Vice President Strategy, Ext. Innovation & Science Policy (R&D), Sanofi
Moderator:
Dr. Martin Mackay, Exe. Vice President and Global Head of R&D, Alexion Pharmaceuticals

Strategy Sessions Co-Chairs
Industry Academic Research Partnerships 
Dr. Barbara Bierer, Senior Vice President- Research, Brigham and Women’s Hospital
Dr. Sridaran Natesan, Vice President, External Innovation (R&D), Sanofi
Dr. José-Carlos Gutiérrez-Ramos, Senior Vice President, Head of BioTherapeutics R&D, Pfizer

External R&D Strategies
Dr. Subir Basak, President- Drug Discovery Services, Jubilant Life Sciences
Dr. RuiPing Dong, Senior Vice President, Head of Emerging Markets R&D, Merck & Co.
Dr. Jeffrey S. Nye, Vice President, Neuroscience Innovation and Scientific Partnership Strategy
Janssen Research and Development, Johnson and Johnson Innovation

Release of Position Paper by Advisory Board members
Presentation of USA-India Chamber of Commerce commissioned Position Paper by Dr. Ajay Dhankhar, Director and Vikas Bhadoria, Principal – McKinsey & Company

Cocktails and Networking Reception

We regret over 100 senior colleagues could not be accommodated in this meeting due to the nature and format of this Strategy Session. Detailed report with recommendations has been sent to the participants, members and key policy makers.

Co-Chairs:
Dr. T. Ramasami, Secretary, Department of Science & Technology
Dr. M.K. Bhan, Former Secretary, Department of Biotechnology
Tsutomu Une, PhD, Member of the Board, Daiichi Sankyo
Richard Mills, JD, Executive Dean, Harvard Medical School
Dr. Naresh Trehan, Chairman, Medanta- The Medicity
Dr. Jagdish Prasad, Director General Health Services, Ministry of Health & Family Welfare
Edward Trimble, MD, MPH Director Global Health, National Cancer Institute
Prof. N.K. Ganguly, Chairman, JIPMER
Karun  Rishi, President, USA-India Chamber of Commerce

Delhi Strategy Session reflected on the action agenda emerging from the global summit held in May  2012 in Boston, explored the implications for the decision makers in India and discussed ideas for the June 21, 2013 Boston Summit. McKinsey & Company facilitated the session. We will take the lead to develop deeper perspectives on these issues through detailed stakeholder discussions, interviews and analyses for discussion at the Boston summit in June.

Discussion were held on Key Enablers:
A.        Industry Academic Partnerships
B.        Talent and Capability Building
C.        External Research Strategies
D.        Building A Regulatory Environment to Foster Innovation

Master of Ceremonies: Dr. William Chin, Executive Dean for Research, Harvard Medical School

Welcome Address: Karun Rishi, President, USA-India Chamber of Commerce

Address By: Dr. Elias Zerhouni, President- Global Research & Development, Sanofi

Strategy Sessions Co-Chairs
Noble Laureate Dr. Phillip Sharp, Institute Professor, Koch Institute for Integrative Cancer Research, MIT
Dr. Sridaran Natesan, Vice President, External Innovation (R&D), Sanofi
Dr. Sanjeev Sinha, Professor- Department of Medicine, All India Institute of Medical Sciences
Dr. RuiPing Dong, Senior Vice President, Head of Emerging Markets R&D, Merck & Co.
Dr. Sandeep Gupta, Sr. Vice President- Early Discovery, Endo Pharmaceuticals
Dr. Rick Connell, VP- External Research Solutions, Pfizer
Sri Mosur, CEO, Global Drug Discovery & Development, Jubilant Life Sciences

Panel: Industry-Academia Partnerships- Can they drive the next wave of innovation?

Panelists:
Dr. Karen Antman, Dean and Provost, Boston University School of Medicine
Dr. Barbara Bierer, Senior Vice President Research, Brigham and Women’s Hospital
Dr. Balakrish Nair, Executive Director, Translational Health Science Technology Institute
Dr. Sridaran Natesan, Vice President, External Innovation (R&D), Sanofi
Dr. Phillip Sharp, Institute Professor, Koch Institute for Integrative Cancer Research
Moderator:
Dr. William Chin, Executive Dean for Research, Harvard Medical School.

Panel: Clinical Research- A practical roadmap to achieve more from India

Panelists:
Dr. Savita Dhillon, Medical Director, Medanta Duke Research Institute
Dr. Nirmal K. Ganguly, Chairman JIPMER & former Director General ICMR
Dr. Roger Glass, Director, Fogarty International Center, National Institutes of Health
Dr. John Orloff, Senior Vice President, Global Development & CMO, Novartis
Dr. John Sundy, Director- Duke Global Proof of Concept Research Network
Moderator:
Dr. Kimberly Wagner, Senior Partner & Managing Director, The Boston Consulting Group

Panel: Drug R&D and Collaborations- Leveraging India to enhance productivity

Panelists:
Dr. Ivan Gergel, Executive Vice President R&D, Endo Pharmaceuticals
Dr. John Leonard, Senior Vice President- Pharmaceuticals R&D, Abbott
Sri Mosur, CEO, Global Drug Discovery & Development, Jubilant Life Sciences
Dr. Rajiv I. Modi, Managing Director, Cadila Pharmaceuticals
Dr. Raja Sekhar Vundru, IAS,  Joint Secretary, Department of Pharmaceuticals, Govt. of India
Moderator:
Dr. Maya Said, Vice President Strategy, External Innovation & Science Policy (R&D), Sanofi

Panel: Funding innovation and investment opportunities in Emerging Markets

Panelists:
Dr. RuiPing Dong, Senior Vice President, Head of Emerging Markets R&D, Merck & Co
Dr. Robert King, Senior Partner, Global Healthcare Group, Goldman Sachs
Utkarsh Palnitkar, Executive Director, Centrum Capital Limited
K.V. Subramaniam, President & CEO, Reliance Life Sciences
Dr. Renu Swarup, Managing Director, Biotechnology Industry Research Assistance Council, Government of India
Moderator:
Bart Janssens, Partner & Managing Director, The Boston Consulting Group

Panel: Oncology- Science and Research Trends

Panelists:
Dr. Nirmal K. Ganguly, Chairman JIPMER & former Director General ICMR
Dr. Rakesh Jain, E.L. Steele Laboratory of Tumor Biology,  MGH Cancer Center
Dr. Amba Nandakumar, Deputy Director General and  Officer-in-Charge,
National Cancer Registry Programme- Indian Council for Medical Research
Dr. Elad Sharon, Senior Investigator, Investigational Drug Branch, National Cancer Institute
Dr. Chris Takimoto, Vice President, Translational Medicine Early Development, J&J
Moderator:
Dr. Raju Kucherlapati, Paul C. Cabot Professor, Department of Genetics, Harvard Medical School

Presentation of USA-India Chamber of Commerce commissioned Position Paper by Bart Janssens, Partner and Rahul Guha, Principal- The Boston Consulting Group

Cocktails and Networking Reception

Co-Chairs:

• Dr. MK Bhan, Secretary to the Government of India, Department of Biotechnology
• Dr. Nirmal K. Ganguly, Chairman JIPMER, past Director General- ICMR
• Dr. T. Ramasami, Secretary to the Government of India, Department of Science & Technology
• Dr. V.G. Somani, Drug Controller General of India
• Dr. Sandeep Gupta, Senior Vice President, Endo Pharmaceuticals
• Karun Rishi, President, USA-India Chamber of Commerce
• DS Brar, Chairman, GVK Biosciences
• KV Subramaniam, CEO, Reliance Life Sciences

Program Summary:
Action agenda emerging from USAIC’s annual global summit
Explore the implications for decision makers in India
Discuss the agenda for the 2012 summit

Master of Ceremonies: Dr. Bill Chin, Executive Dean for Research, Harvard Medical School

Opening remarks: Karun Rishi, President-USA-India Chamber of Commerce

Panel: Drug Discovery and Collaborative Research: Increasing the odds of success

Panelists:
Dr. Martin Fitchet, Chief Operating Officer, Johnson & Johnson Pharma R&D
Dr. Ivan Gergel, Executive Vice President R&D, Endo Pharmaceuticals
Dr. John Leonard, Senior Vice President- Pharmaceuticals R&D, Abbott
Sri Mosur, CEO, Global Drug Discovery & Development, Jubilant Life Sciences
Dr. Peter Mueller, Executive Vice President- Global R&D, Vertex Pharmaceuticals
Moderator:
Dr. Bill Chin, Executive Dean for Research, Harvard Medical School

Panel: “Show me the Money”: Funding innovation, investment opportunities and cross border M&A trends in the BioPharma & Healthcare

Panelists:
Hari Bhartia, Founder & Co-Chairman, Jubilant Bhartia Groups
Dr. Ansbert Gadicke, Founder & Managing Director, MPM Capital
Robert King, Senior Partner, Global Healthcare Group, Goldman Sachs
Joel Marcus, Chairman & CEO, Alexandria Real Estate Equities
K.V. Subramaniam, President, Reliance Life Sciences
Moderator:
Jeff Elton, Founder & CEO, KEW Group

Panel: Industry-Academia Partnerships: Can they be the engine of a new wave of innovation?

Panelists:
Dr. Harris Berman, Dean ad interim, Tufts University School of Medicine
Dr. M.K. Bhan, Secretary, Department of Biotechnology, Govt. of India
Dr. Vijay Chandru, Chairman & CEO, Strand Life Sciences
Julius Knowles, Head, Platforms, Strategic Alliances, NIBR (Novartis)
Dr. Lansing Taylor, Director, Drug Discovery Institute, University of Pittsburg
Moderator:
Dr. Barry Bloom, Distinguished Service Professor, Harvard School of Public Health

Panel: Diabetes – Science, Research trends and Market Opportunities

Panelists:
Dr. Martin Fitchet, Chief Operating Officer, Johnson & Johnson Pharma R&D
Dr. William Mezzanotte, Vice President- Global Products Leadership, AstraZeneca
Dr. Steven Shoelson, Professor of Medicine, Joslin/Harvard Medical School
Kiran Mazumdar-Shaw, Chairman & Managing Director, Biocon
Dr. Suri Venkatachalam, Founder & CEO, Connexios Life Sciences
Moderator:
Dr. Paul Strumph, Vice President-Therapeutic Strategy Lead, Quintiles

Panel: Moving the needle on Drug Development, Clinical Research & other Healthcare opportunities

Panelists:
Dr. Nora Dyer, Head of Search & Evaluation, Novartis Pharmaceuticals
Dr. Nirmal Ganguly, Chairman JIPMER, & ex-Director General ICMR
Krishna Kanumuri, Chief Executive Officer, Sai Advantium
Sanjay Mittal, Director- Research & Clinical Cardiology, Medanta -The Medicity
Debasish Roychowdhury, Head of Global Oncology, Sanofi
Moderator:
Dr. Gunther Winkler, Senior Vice President, Biogen Idec

Presentation of USA-India Chamber of Commerce commissioned annual Position Paper by Bart Janssens, Partner, The Boston Consulting Group

Strategy Sessions Co-Chairs
Richard D. Connell, PhD, Vice President and Head of Asia Research, Pfizer
Sandeep Gupta, PhD, Senior Vice President of Drug Discovery & Early Development, Endo Pharmaceuticals
Sri Mosur, President & CEO, Global Drug Discovery & Development, Jubilant Life Sciences
Isaac T. Kohlberg, Senior Associate Provost & Chief Technology Development Officer, Harvard
Sridaran Natesan, PhD, Scientific Site Head – R&D & Head External Innovation & Partnering- NE, Sanofi

Cocktails and Networking Reception 

Master of Ceremonies: Dr. Martin Mackay, President Global R&D, Pfizer

Opening Remarks: Karun Rishi, President, USA India Chamber of Commerce

Panel: Industry-Academia Partnerships

Panelists:
Dr. Allen M Spiegel, Dean, Albert Einstein College of Medicine, Yeshiva University
Balu Balasubramanian, PhD, Managing Director, BMS-Biocon R&D Center
Dr. David Golan, Dean of Graduate Education, Harvard Medical School
Dr. Nirmal Ganguly, Chairman JIPMER, Ex-Director General ICMR
Kiran Mazumdar-Shaw, Chairman & Managing Director, Biocon
Moderator:
Dr. Barry R. Bloom Distinguished Service Professor, Harvard School of Public Health

Panel – Funding innovation, investment opportunities and cross
border M&A trends in US-India BioPharma & Healthcare

Panelists:
Joel Marcus, Chariman and CEO, Alexandria
K.V. Subramaniam, President & CEO, Reliance Life Sciences
Dr. Ansbert Gadicke, Founder & Managing Director, MPM Capital
Utkarsh Palnitkar, Executive Director, Centrum Capital Limited
Brian Atwood, Founding Partner, Versant Ventures
Moderator:
Jeff Elton, Founder & CEO, KEW Group

Presentation by: Dr. Marc Cluzel, Executive Vice President & Global Head of R&D, Sanofi aventis

Presentation by: Dr. Mervyn Turner, Chief Strategy Officer & Senior Vice President Emerging Markets R&D, Merck & Co.

Panel: Collaborative Research and Drug Discovery

Panelists:
Dr. David Lacey, Senior Vice President- Research, Amgen
Dr. Peter Mueller, Executive Vice President, Global R&D & CSO, Vertex Pharmaceuticals
Sri Mosur, Chief Executive Officer, Jubilant Biosys
Dr. Paul Stoffels, Global Head- R&D Pharma, Johnson & Johnson
Davinder Brar, Chairman, GVK Biosciences
Moderator:
Dr. Martin Mackay, President PharmaTherapeutics R&D, Pfizer

Presentation by: Dr. Rod MacKenzie, Senior Vice President & Head of Worldwide Research, PharmaTherapeutics, Pfizer

Panel: Drug Development, Clinical Research & Healthcare opportunities

Panelists:
Dr. Michael Rosenblatt, Executive Vice President & Chief Medical Officer, Merck & Co.
Dr. Sanjay Mittal, Director-Clinical Cardiology & Research, Medanta, The Medicity
Dr. Nirmal Ganguly, Chairman JIPMER, Ex-Director General ICMR
Dr. Paul Stoffels, Global Head- R&D Pharma, Johnson & Johnson
Dr. Robert Taber Vice Chancellor- Corporate & Venture Devp, Duke University Medical
Moderator:
Alka Goel, Associate Principal, McKinsey & Company

Presentation of USA India Chamber of Commerce commissioned McKinsey & Company Position Paper
Ajay Dhankar and Vikas Bhadoria

Closing Remarks: Dr. Gunther Winkler, Sr. Vice President, Biogen Idec

Cocktails and Networking Reception

Chaired by Honorable Srikant Jena, Minister of State for Chemicals & Fertilizers Opening Remarks- Karun Rishi, President, USA-India Chamber of Commerce Moderated by- Prof. Barry Bloom, Past Dean, Harvard School of Public Health.

Organized by Department of Pharmaceuticals, Government of India in association with USA India Chamber of Commerce

Click here for program details

Opening remarks Prof. Barry R. Bloom, Harvard School of Public Health
Remarks Karun Rishi, President, USA-India Chamber of Commerce

Q&A and Open Discussion

Business Roundtable open to C level and senior executives from Healthcare, Pharma, Biotech, Medical Devices, Investment firms and Academia.

Master of Ceremonies: Dr. Martin Mackay, President Global R&D, Pfizer

Opening Remarks: Karun Rishi, President-USA-India Chamber of Commerce

Release of USA-India Chamber of Commerce commissioned McKinsey & Company Position Paper by Dr. Martin Mackay, President Global R&D, Pfizer

Panel: Healthcare, Clinical Research and Industry-Academic Partnerships

Panelists:
Dr. Gerald Keusch, Associate Provost, BU School of Public Health
Dr. David Lacey, Senior Vice President & Head of Research, Amgen
Dr. Michael Rosenlatt, Dean Tufts University School of Medicine
Joe Smith, MD, PhD, Vice President-Emerging Technologies, Johnson & Johnson
Sridhar Mosur, Chief Executive Officer, Jubilant Biosys
Moderator:
Dr. William Chin, Vice President – Discovery Research & Clinical Investigation, Eli Lilly & Company

Introduction by Manni Kanti Pudi, President, GVK BioSciences

Keynote Address: Dr. Martin Mackay, President, Pfizer Global Research & Development

Panel: Funding Innovation, Cross Border Investment and M&A Trends

Panelists:
K.V.Subramaniam, President, Reliance Life Sciences
Jeff Collins, Executive in Residence, Pappas Ventures
Jeffrey Elton, Life Sciences Investor & Consultant
George Bickerstaff, Managing Director, CRT Investment Banking
Shrikumar Suryanarayan, Director General, ABLE
Moderator:
Glen Giovanneti, Global Biotechnology Leader, Ernst & Young

Introduction: Banashri Bose Harrison, Minister (Commerce), Embassy of India

Keynote Address by Nobel Laureate Dr. Sidney Altman

Presentation by Department of Pharmaceuticals, Government of India. Paresh Johri, Deputy Secretary

Panel: Drug discovery, Development and Collaborative Research

Panelists:
Robert Armstrong, PhD, Vice President, Global External R&D, Eli Lilly
Venkat Jasti, Chairman & CEO, Suven Life Sciences
Ismail Kola, PhD, Senior Vice President- Discovery Research & Chief Scientific Officer, Schering-Plough
CSN Murthy, Chief Executive Officer, Aurigene Discovery
Dr. John Thompson, Vice President, Strategic Research Alliances, Vertex
Moderator:
Ramesh Srinivasan, Principal, McKinsey and Company

Introduction: Reid Leonard, PhD, Executive Director, External Research & Licensing, Merck & Co.

Presentation of distinguished services award to Dr. Barry R. Bloom
Introduction by Dr. Gerald Keusch, Associate Provost, BU School of Public Health
Award Presentation by Dr. Martin Mackay and Karun Rishi

Address by Dr. Barry R. Bloom, Harvard University Distinguished Service Professor and Joan L. and Julius H. Jacobson Professor of Public Health at the Department of Immunology and Infectious Diseases, Harvard School of Public Health

Closing Remarks – James Mullen President & CEO, Biogen Idec

Cocktails and Networking Reception

Master of Ceremonies: Hon. Andrew Maguire, PhD, Executive Director-GAVI

Opening remarks: Karun Rishi, President USA-India Chamber of Commerce

Presentation of USA-India Chamber of Commerce commissioned McKinsey & Company Position Paper

Panel: Drug Discovery, Collaborative Research and Strategic Alliances

Panelists:
Dr. William Chin, Vice President – Discovery Research, Eli Lilly
Venkat Jasti, Vice Chairman & CEO, Suven Life Sciences
Dr. Peter Mueller, Exe. Vice President & CSO, Vertex Pharmaceuticals
Barbara Yanni, Chief Licensing Officer, Merck & Co
Dr. Rashmi Barbhaiya, Co-Founder and CEO, Advinus Therapeutics

Official Release of Position Paper and Keynote address by Honorable Kapil Sibal, Minister of Science & Technology and Earth Sciences, Government of India

Panel: Funding Innovation, Investment Opportunities, Cross Border M&A trends

Panelists:
Frederick Frank, Vice Chairman & Director, Lehman Brothers
Dr. Helmut M. Schühsler, Managing Partner, TVM Capital
Tom Andrews, Senior Vice President, Alexandria Real Estate Equities
Sri Mosur, President & CEO, Jubilant Biosys
Dr. Jasmin Patel, Managing Director, Fidelity Capital Management (India)

Keynote address by Dr. Surinder Singh, Drug Controller General of India

Introduction: James Mullen, President & CEO, Biogen Idec and past Chairman, Biotechnology Industry Organization (BIO)

Keynote address by Dr. Joshua Boger, President & CEO, Vertex Pharmaceuticals and Chairman, Biotechnology Industry Organization (BIO)

Panel: Drug Development & Manufacturing, Clinical Research and In/Out Licensing

Panelists:
Dr. Mark Powell, Sr VP & Worldwide Head-Pharmaceutical Development, Bristol Myers & Squibb
Gregg Alton, Senior Vice President, Gilead Sciences
Dr. Gunther Winkler, Senior Vice President, Biogen Idec
Dr. Arun Chandavarkar, Chief Operating Officer, Biocon
Dr. Dianne Kikta, Vice President Global Clinical, Wyeth
Dr. Sreeni Devidas, Vice President, GVK BioSciences

Closing Remarks: Dr. Helmut M. Schühsler, Managing Partner, TVM Capital and Board Member, USA-India Chamber of Commerce

Cocktails and Networking Reception

Welcome address: Karun Rishi, President, USA-India Chamber of Commerce

Opening remarks: James C. Mullen, Chairman Biotechnology Industry Organization (BIO), CEO & President, Biogen Idec

Release of USA-India Chamber of Commerce commissioned Ernst & Young Position Paper

Panel: Discovery, Development, IP & Regulatory Issues

Panelists:
Dr. Alan Smith, Chief Scientific Officer, Genzyme
Dr. Peter Mueller, Chief Scientific Officer, Vertex Pharmaceuticals
Dr. Rashmi H.Barbhaiya, CEO and MD, Advinus Therapeutics
Dr. Sridhar Mosur, Managing Director, Jubilant Chemsys
Dr. Arun Chandavarkar, Chief Operating Officer, Biocon
Moderator:
Dr. David C U’Prichard, Partner, Red Abbey Venture Partners and Care Capital

Keynote Address:
Dr. M.K.Bhan, Secretary to the Govt of India, Department of Biotechnology
Introduction to Dr. MK Bhan by Joel Marcus, Chairman, Alexandria Real Estate Equities

Panel: Investment Opportunities, Cross Border Investments, M&A Trends in US-India Life Sciences industry

Panelists:
Dr. Helmut M. Schühsler, Managing Partner, TVM Capital
Dr. David Gluckman, MD & Head of European Life Sciences, Lazard
George Bickerstaff, Managing Director, CRT Capital Group
Hari Bhartia, Founder & Co-Chairman, Jubilant Bhartia Group
Dr. Stephen Knight, Managing Partner, Fidelity Biosciences
Moderator:
Utkarsh Palnitkar , Partner-Transaction Advisory Services, Industry Leader – Health Sciences, Ernst & Young

Closing remarks: Dr. Helmut M. Schühsler, Managing Partner, TVM Capital and Board Member, USA-India Chamber of Commerce

Cocktails & Networking Reception

India Healthcare Business Roundtable with Dr. Anbumani Ramadoss, Honorable Union Minister of Health, Government of India and Prof. N.K. Ganguly, Director General, Indian Council of Medical Research (ICMR).

Opening remarks: Prof. Barry R. Bloom, Dean, Harvard School of Public Health
Remarks: Karun Rishi, President, USA-India Chamber of Commerce
Q&A and open discussion

• Opportunities in the Indian Healthcare industry
• Opportunities in India for US Healthcare, Biotech, Pharma and Medical Device companies
• Public-Private partnership in Indian Healthcare

Business Roundtable open to C level and senior executives from Healthcare, Pharma, Biotech, Medical Devices, Investment firms and Academia.

   

Special focus on opportunities for US SME companies in India. The two day conference besides several keynotes will have sessions on IT, ITeS, Retail, Real Estate, Food Processing, Auto and Auto Components, Financing, Entrepreneurship, Policy, Market Access, Emerging sectors and Export opportunities.

Senior policy makers and key executives from Walmart, Citigroup, Bank of America, SBA, Coca-Cola, Kelloggs, Tishman Spyer, Parsons, IBM, Hero Group, UPS, Bharti, General Motors, EXIM Bank, and Proctor & Gamble etc will participate in the panel discussions.

Opening Remarks: Karun Rishi, President, USA-India Chamber of Commerce
Remarks by Prof K. Srinath Reddy, Professor and Head, Department of Cardiology, All India Institute of Medical Sciences (AIIMS) and President, Public Health Foundation of India
Remarks by Prof. Barry R. Bloom, Dean, Harvard School of Public Health

Q&A and open discussion

Closing Remarks: Stephen Knight, Managing Partner, Fideliity Biosciences

The discussion will focus on:

• Opportunities for US Pharma, Biotech and Medical Device companies
• Public-Private partnership in healthcare
• Public Health Foundation of India
• AIIMS research initiatives in electrophysiology, cardiomyopathies, gene therapy and stem cell therapy

Prof Reddy was recently appointed President of the Public Health Foundation of India. Dr. Reddy Chairs numerous healthcare commissions and committees in India and internationally.

USA-India Chamber of Commerce is pleased to support the Business Development Mission led by Amb. Franklin L. Lavin, Under Secretary for International Trade, U.S. Department of Commerce. This precedent-setting initiative, potentially involving the largest ever overseas delegation of its kind led by a U.S. Government official, will serve as the capstone of a year of successful activities conducted under the auspices of the U.S.-India Commercial Dialogue, honoring the commitment of President Bush and Indian Prime Minister Manmohan Singh to revitalize bilateral trade discussions.

This is a great opportunity to get access to IndiaÂ’s high-level business, industry, and government representatives and opportunities to gain timely insights into the countryÂ’s trade and investment climate.

Program

Opening Remarks: Karun Rishi, President, USA-India Chamber of Commerce
Introduction: Nigel Thompson, Executive Director, Merck
Business Roundtable with David Bohigian, Assistant Secretary, U.S. Department of Commerce
Closing Remarks: Michael Fondo, Director, Fidelity Investments

Assistant Secretary BohigianÂ’s Market Access and Compliance (MAC) division identifies and overcomes trade barriers, resolves trade policy issues, and ensures that our trading partners fully meet their obligations under our trade agreements. MAC ensures access to world markets for American companies.

MAC focuses on issues such as: Intellectual Property and Piracy, Quotas, Standards, Customs, Transparency and Contract Sanctity, National Treatment and Good Governance.

This roundtable is only for senior executives.

USA-India Chamber of Commerce and USIBC present an Executive Luncheon Business Roundtable with Satwant Reddy, Secretary to Government of India, Ministry of Chemicals. She is the top ranking official in the ministry. Her portfolio includes the regulation of all state-owned chemical companies, pharmaceuticals, and petrochemicals. Among other things, she is tasked responsibility for formulating India ’s data exclusivity and pharmaceutical price control policies.

Dinner meeting with Ms. Satwant Reddy, Secretary to Government of India, Ministry of Chemicals & Petrochemicals and Prof. Josh Lerner, Jacob H. Schiff Professor of Investment Banking, Harvard Business School and author of the book:  ‘Innovation and Its Discontents’: How Our Broken Patent System is Endangering Innovation and Progress.